Trevi Therapeutics, Inc. Appoints Lisa Delfini as Chief Financial Officer
August 09, 2021 at 05:29 pm
Share
On August 9, 2021, Trevi Therapeutics, Inc. announced the hiring of Lisa Delfini, who will serve as the Company’s Chief Financial Officer and principal financial officer upon her start date of August 9, 2021. Ms. Delfini, 51, served as a Financial Accounting and Advisory Services Partner at Marcum LLP from 2015 until August 6, 2021.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed k-opioid receptor agonist and mu-opioid receptor antagonist. It is conducting Phase IIb/III clinical trial of Hadguvio in patients with severe pruritus associated with prurigo nodularis. It has also conducted a Phase II clinical trial of Haduvio for chronic cough in patients with IPF, which is referred to as the Phase II CANAL trial. The Companyâs Haduvio development programs include Chronic Cough in IPF Program, RCC Program and Prurigo Nodularis Program. The Companyâs subsidiary is Trevi Therapeutics Limited.
TREVI THERAPEUTICS, INC. 
